Northern Trust Corp Indaptus Therapeutics, Inc. Transaction History

Northern Trust Corp

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.51 - $1.9 $30 - $38	20 Added 0.16%	12,918 $23,000
Q3 2022 Nov 14, 2022	BUY	$2.16 - $3.33 $5,620 - $8,664	2,602 Added 25.27%	12,898 $28,000
Q1 2022 May 13, 2022	BUY	$3.19 - $6.17 $32,844 - $63,526	10,296 New	10,296 $41,000

605K

Ticker INDP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,258,600
Market Cap $8.09M
Description
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B v...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.